Connect your AI

Bio-Rad Laboratories, Inc. BIO.B Price / book

Price / book at other companies

AbbottABT

3.4×-1.3×

Becton, Dickinson and CompanyBDX

1.9×-0.8×

Thermo Fisher ScientificTMO

3.5×-0.3×

DanaherDHR

2.5×-0.4×

Agilent TechnologiesA

4.6×-0.4×

RevvityRVTY

1.4×-0.3×

Other financials

Income statement

Revenue$592.1M+1.1%

Gross profit$309.4M+1.1%

Operating income$34.1M+43.9%

Net income-$527.1M-924%

EPS (diluted)-$19.55-954%

Balance sheet

Cash & equivalents$509.0M-2.7%

Total debt$987.3M-28.4%

Total equity$6.9B+2.6%

Total assets$9.8B+2.8%

Cash flow

Operating cash flow$108.1M-16.8%

CapEx$30.0M-12.8%

Free cash flow$78.1M-18.2%

Valuation

Market cap$7.56B+10.3%

Enterprise value$8.04B+4.2%

P/E44.8×—

P/S2.9×+0.2×

Profitability

Gross margin51.9%-1.6pp

Operating margin8.8%-3.1pp

Net margin6.5%+3.4pp

FCF margin13.8%-0.2pp

Returns & leverage

Return on equity2.5%+1.3pp

Debt / equity0.1×-0.1×

Current ratio3.2×-2.8×

Where this comes from

Calculated from Bio-Rad Laboratories, Inc.’s reported figures.

market cap/total stockholders equity=1.1×

Based on the most recent quarter.

The official record: Bio-Rad Laboratories, Inc.’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Bio-Rad Laboratories, Inc.'s price / book.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Bio-Rad Laboratories, Inc.'s price / book?: Bio-Rad Laboratories, Inc. (BIO.B) reported price / book of 1.1× in Q1 2026.
How has Bio-Rad Laboratories, Inc.'s price / book changed year-over-year?: Bio-Rad Laboratories, Inc.'s price / book increased by 7.5% year-over-year, from 1× to 1.1×.
What is the long-term trend for Bio-Rad Laboratories, Inc.'s price / book?: Over 5 years (2020 to 2025), Bio-Rad Laboratories, Inc.'s price / book has grown at a -9.1% compound annual growth rate (CAGR), from 1.8× to 1.1×.
What does price / book mean?: Market capitalization at the quarter end divided by shareholders' equity. The premium (or discount) the market assigns to the company's book equity.